vimarsana.com

Latest Breaking News On - Multiple ascending oral - Page 1 : vimarsana.com

Ceapro Inc Reports Financial Results for First Quarter 2023 and Provides Corporate Update

– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May . | May 25, 2023

United statesBeta glucanJenene thomasGillesr gagnonGilles gagnonCorporate communications advisorPipeline developmentClinical developmentAngiogenesis foundationVenture exchangeMontreal heart instituteMcmaster universityCeapro incExpanded technologyFirst in human studyAssess safety

Ceapro Inc Receives Approval from Health Canada to

- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the Montreal Heart.

Gilles gagnonJenene thomasGillesr gagnonJean claude tardifMontreal heart instituteCorporate communications advisorCorealis pharma incMontreal heart institute research centerMontreal health innovations coordinating centerJenene thomas communicationsCeapro incHealth canadaHealth innovations coordinating centerFirst in human studyAssess safetyMultiple ascending oral

vimarsana © 2020. All Rights Reserved.